ReviewPharmacoEconomics2015
The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA.
Review in PharmacoEconomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Effect of a herbal extract powder (YY-312) from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode on body fat mass in overweight adults: a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial.BMC complementary and alternative medicine · 2017Trial
- A scoping review of obesity policies and reimbursement landscape: global insights and lessons for Thailand.Implementation science communications · 2026Article
- The 'Obesity First' approach: Redefining the future of healthcare.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Barriers and enablers to effective weight management for people living with overweight and obesity: A rapid scoping review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Article
- Global barriers to decision makers for prioritizing interventions for obesity.International journal of obesity (2005) · 2025Article
- Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association.Circulation · 2024Review
- Weight-centric prevention of cancer.Obesity pillars · 2024Review
- Policy Interventions to Enhance Medical Care for People With Obesity in the United States-Challenges, Opportunities, and Future Directions.The Milbank quarterly · 2024Article
- Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE).Obesity science & practice · 2024Article
- Caregiver Burden and Its Relationship to Health-Related Quality of Life in Craniopharyngioma Survivors.The Journal of clinical endocrinology and metabolism · 2023Article
- Breaking down silos: the multifaceted nature of obesity and the future of weight management.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Review
- The Relative Value of Anti-Obesity Medications Compared to Similar Therapies.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Medicaid expansion and health care access for individuals with obesity in the United States.Obesity (Silver Spring, Md.) · 2022Article
- The Case for Early Use of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Patients with Comorbid Diabetes and Metabolic Syndrome.Life (Basel, Switzerland) · 2022Article
- Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors.Current atherosclerosis reports · 2021Review
- Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.Advances in therapy · 2021 · on this mapReview
- Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- The Societal Value of Broader Access to Antiobesity Medications.Obesity (Silver Spring, Md.) · 2020Article
- Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study.Clinical obesity · 2019Article
- A call to action to inform patient-centred approaches to obesity management: Development of a disease-illness model.Clinical obesity · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has become a serious public health problem that has stimulated primordial and primary prevention efforts, and a triad of management options (lifestyle, pharmacotherapy, and surgical interventions). A growing body of evidence supports the need for a multi-pronged, clinic-based approach that leverages the synergy between pharmaceutical and lifestyle modification. Recent US policy changes-namely, the passage of the Patient Protection and Affordable Care Act coupled with recognition of obesity as a disease by the American Medical Association-suggest that financial incentives and attitudes towards obesity management are changing. This paradigm shift has implications for current and future obesity pharmacotherapy. However, barriers to pharmacotherapy utilization include patient and physician perceptions of modest efficacy, historical safety issues, regulatory obstacles, and lack of reimbursement. The shifting attitudes and challenges associated not only with a multi-payer system, but also the lack of clearly defined cross-payer reimbursement strategies, prompted a survey to determine coverage for obesity treatment. Participants indicated that federal/state mandates and growth of quality-driven healthcare initiatives will eventually drive wider pharmacotherapy reimbursement within 1-5 years. There are signs that federal/state programs are already moving towards reimbursement by improving quality measures to track obesity outcomes and reduce costs. Future research on clinical and economic outcomes of combination weight-management programs coupled with innovative approaches (e.g., eHealth) in the real-world setting that demonstrate value to patients, healthcare providers, payers, and employers will help reshape obesity management by reducing barriers and broadening reimbursement coverage for anti-obesity pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.